Immuno-Oncology 360° Community News’ Post

EACR 2025 Congress abstract topics announced Lisbon, Portugal, 16-19 June 2025 #cancergenomics #epigenetics #bioinformatics #computationalbiology #tumour #drugresistance #signalingpathways #carcinogenesis #immunotherapy #radiationoncology #radiobiology #cancercellbiology

🎉Exciting News in Chronic GvHD Treatment!🎉 On August 14, 2024, Incyte and Syndax announced FDA approval of Niktimvo™ (axatilimab-csfr), the first CSF-1R monoclonal antibody approved for treating chronic graft-versus-host disease (GvHD) in patients unresponsive to at least two prior therapies. Specifically, Niktimvo helps to mitigate the chronic inflammatory and fibrotic responses characteristic of this condition. At Biocytogen, we are committed to supporting the scientific community with advanced research tools. We have developed a range of GvHD mouse models leveraging our proprietary B-NDG immunodeficient mice and humanized mouse models based on these B-NDG mice. These models offer critical insights into immune responses, facilitating the development of novel treatments. 🐭 Contact us today to explore how our GvHD mouse models can advance your research and contribute to the future of GvHD treatment! 💡Read more: https://lnkd.in/gVw5eUAR #GvHD #Immunology #Biotech #HealthcareInnovation #FDAApproval #ResearchTools #Biocytogen

Hevylite Chains - Clinical Utility Empower your clinical practice with the superior diagnostic capabilities of Hevylite assays, and enhance your approach to managing Multiple Myeloma. When monitoring IgG κ&λ and IgA κ&λ Multiple Myeloma patients, Hevylite assays can provide the following additional information: -Hevylite assays are useful for monitoring monoclonal gammopathies such as Multiple Myeloma and oligo-secretory Multiple Myeloma -These assays can detect monoclonality even when total immunoglobulin levels are within the normal range -Hevylite assays may identify plasma cell clonality -An abnormal κ/λ (IgG, IgA or IgM) ratio with suppression of the uninvolved immunoglobulin may provide valuable information about a patient's immunoglobulin response. Extract from: https://lnkd.in/dbbCygfE #Hevylite #ClinicalUtility #MultipleMyeloma #MonoclonalGammopathy #Diagnostics #PlasmaCell #HealthcareExcellence #Immunology #PatientCare #LaboratoryMedicine * Through quantification of heavy and light chain isotypes

DID YOU KNOW❓ mRNA technology, first used in COVID vaccines, is now being tested in clinical trials to fight cancer and other diseases! 🧬💉 What do you think about this breakthrough in medicine? Could this be the future of healthcare? Share your thoughts! 👇 #mRNA #CancerResearch #MedicalBreakthrough #ClinicalTrials #HealthInnovation #clinogenesis #clinogenesisresearchinstitute #CGRI #fyp #clinicalresearch #CR #ClinicalTrials

Today marks the final day of the World Vaccine Conference in Washington D.C., and our team at Cellular Technology Limited is here to support your immunology research journey! As a leading Contract Research Organization (CRO), we specialize in immune monitoring solutions that drive innovation and accelerate drug development processes. Join us at booth 506 to explore how our cutting-edge technologies can enhance your vaccine development initiatives. Let's discuss how Cellular Technology Limited can be your trusted partner in achieving your immune monitoring goals. See you there! #WorldVaccineConference #ImmuneMonitoring #ELISPOT #WVC2024 #CTL #CRO

Immunology is AbbVie’s world. That is the takeaway from ZoomRx’s analysis of HCP’s perceptions, who overwhelmingly see AbbVie as the TOP in Immunology field in terms of multiple attributes such as innovation and patient centricity 🙌. Most HCPs ranked AbbVie as one of the top three companies in #each category, causing it to score 100 on ZoomRx’s perception scale, while the second to it scored 70 !! 𝙋𝙧𝙤𝙪𝙙 𝙬𝙤𝙧𝙠𝙞𝙣𝙜 𝙖𝙩 𝘼𝙗𝙗𝙑𝙞𝙚 𝙩𝙤 𝙝𝙚𝙡𝙥 𝙡𝙚𝙖𝙫𝙚 𝙧𝙚𝙢𝙖𝙧𝙠𝙖𝙗𝙡𝙚 𝙄𝙈𝙋𝘼𝘾𝙏 𝙤𝙣 𝙄𝙢𝙢𝙪𝙣𝙤𝙡𝙤𝙜𝙮 𝙥𝙖𝙩𝙞𝙚𝙣𝙩𝙨. The research results: >150 HCPs, Q1-23 Read the full report https://lnkd.in/dJeVcyTs #immunology #pharmaindustry #patientcentricity #abbvielife #AbbVieLife

What challenges can IndEx-2 overcome? We asked our Senior Study Manager, Dr Gavin Meehan. “On target/off tumour effects, in which healthy cells are killed by therapeutics, is a major concern in immuno-oncology. ❌ Current methods to measure on target/off tumour effects involve using different cell lines with different expression levels. This can be costly, and the confounding factors of different cell backgrounds can make results difficult to interpret. ✔️ IndEx-2 solves these issues by providing a finely titratable system on cells with the same background. This allows for a robust, accurate and cost-effective system for assessing on target/off tumour effects.” Discover more. 🔎⬇️ https://bit.ly/3XjnYdN #IndEx2 #immunology #immunotherapy #drugdiscovery #bioassays #CRO

Read this new article in the European Journal of Immunology referencing our renowned QuickSwitch™ Custom Tetramer Kits! https://hubs.li/Q02vRTw70 Learn more about QuickSwitch™: https://hubs.li/Q02vRTWr0

🌟Autoimmune T1D in a dish: Screen your T-Cell inhibitors using HLA-A2 EndoC-βH5®🌟 HLA-A2 EndoC-βH5® cells enhance clinical accuracy of your beta cell protection strategy by recapitulating T cell-mediated beta cell killing in vitro. Expressing the crucial Type 1 Diabetes beta cell marker HLA-A*02, these cells are specifically killed by HLA-A2 restricted CD8 T lymphocytes. Discover more : https://lnkd.in/eezE82Wj Contact us : https://lnkd.in/enfxhMRu Guillaume Costecalde Bruno Blanchi Hamza OLLEIK Nathan GUIRAUD Clotilde Dumas Marion Taurand Charlotte Cavanihac Clara Flurin Marion Pilette #DiabetesResearch #Type1Diabetes #HLAA2EndoCBH5 #BetaCell #CD8TCells #Killingassay #cells #CellModel #InVitro #Research #Diabetes #Immunology #ResearchModel #Assay #TranslationalResearch #Innovation #Biotechnology #DrugDevelopment #Technology #MedicalResearch #Biomedical #Bioengineering #Science #HumanCellDesign

🌟Autoimmune Type 1 Diabetes in a dish using HLA-A2 EndoC-βH5®🌟 Recapitulate HLA-A*02 positive human functional beta cells attack by CD8+ cytotoxic T cells Histocompatibility antigen HLA-A*02 is a pancreatic beta cells critical marker presents on a large number of type 1 diabetic patients. HLA-A2 Endoc-BH5® is a cellular model expressing HLA-A*02 that can replicate in vitro the recognition and destruction of beta cells by CD8+ cytotoxic T cells. Discover more : https://lnkd.in/eezE82Wj Contact us : https://lnkd.in/enfxhMRu #DiabetesResearch #Type1Diabetes #HLAA2EndoCBH5 #BetaCell #CD8TCells #Killingassay #CellModel #InVitro #Research #Diabetes #Immunology #ResearchModel #Assay #TranslationalResearch #Innovation #Biotechnology #DrugDevelopment #Technology #MedicalResearch #Biomedical #Bioengineering #Science #HumanCellDesign